Abstract

Qa-1 epitopes, the peptides that bind to non-classical major histocompatibility complex Ib Qa-1 molecules and are recognized by Qa-1-restricted CD8+ regulatory T (Treg) cells, have been identified in pathogenic autoimmune cells that attack myelin sheath in experimental autoimmune encephalomyelitis (EAE, an animal model for multiple sclerosis [MS]). Additionally, immunization with such epitopes ameliorates the EAE. However, identification of such epitopes requires knowledge of the pathogenic autoimmune cells which are largely unknown in MS patients. Hence, we asked whether the CD8+ Treg cells could directly target the myelin sheath to ameliorate EAE. To address this question, we analyzed Qa-1 epitopes in myelin oligodendrocyte glycoprotein (MOG that is a protein in myelin sheath). Here, we report identification of a MOG-specific Qa-1 epitope. Immunization with this epitope suppressed ongoing EAE, which was abrogated by CD8+ T cell depletion. Additionally, the epitope immunization activated the epitope-specific CD8+ T cells which specifically accumulated in the CNS-draining cervical lymph nodes. Finally, CD8+ T cells primed by the epitope immunization transferred EAE suppression. Hence, this study reveals a novel regulatory mechanism mediated by the CD8+ Treg cells. We propose that immunization with myelin-specific HLA-E epitopes (human homologues of Qa-1 epitopes) is a promising therapy for MS.

Highlights

  • Multiple sclerosis (MS) is a chronic and debilitating disorder in the central nervous system (CNS)

  • We investigated potential Qa-1 epitopes in myelin oligodendrocyte glycoprotein (MOG) that is one of the myelin proteins in myelin sheath

  • Portion of CD8+ T cells in the CD8+ T cell lines reactive to the pool of OLPs covering the whole length of mouse MOG is Qa-1b restricted

Read more

Summary

Introduction

Multiple sclerosis (MS) is a chronic and debilitating disorder in the central nervous system (CNS). Antigen-specific therapy is the logical pathway to achieve this goal[5,6] In this regard, the major purpose of an antigen-specific therapy is to instruct potentially pathogenic myelin-specific autoimmune cells, which are responsible for the EAE and MS7–11, to become myelin-specific regulatory T (Treg) cells. The major purpose of an antigen-specific therapy is to instruct potentially pathogenic myelin-specific autoimmune cells, which are responsible for the EAE and MS7–11, to become myelin-specific regulatory T (Treg) cells Such Treg cells can arrest the autoimmune attacks on the myelin sheath without compromising the immune defense mechanisms. Among numerous antigen-specific therapies that are being investigated, the strategies that utilize regulatory Qa-1 epitopes to enhance the function of Qa-1-restricted CD8+ Treg cells have unique advantages. The following is a detailed description of our findings from this study

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call